Do you think 8-weeks of Sofo/Ledi would show superior SVR rates to 12-weeks of Sofo/Ledi in GT1A patients within a large study (n=600)?
I certainly have not written off the possibility that GILD's 8-weeks regimen would be non inferior to a 12-weeks one. Riba sparing plus only 8 weeks seems too much of a stretch, but the real option might be as mentioned before - 8 weeks with Riba vs 12 weeks without. In this case I don't expect the shorter duration treatment to have a meaningful commercial advantage unless other DAA regimens would include Riba.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.